SCHEMBL6867577

SCHEMBL6867577

CCn1c(C(=O)c2cc3cc(OC)ccc3[nH]2)cc2ccccc21

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 7/20 0.63
PDGFRB P09619 6/20 0.63
PDGFRA P16234 6/20 0.63
MEN1 O00255 1/20 0.59
CYP1A2 P05177 1/20 0.59
CYP3A4 P08684 1/20 0.59
CYP2C9 P11712 1/20 0.59
TSHR P16473 1/20 0.59
KMT2A Q03164 1/20 0.59
HDAC6 Q9UBN7 1/20 0.59
KDM4E B2RXH2 1/20 0.53
NPC1 O15118 1/20 0.53
ALDH1A1 P00352 1/20 0.53
LMNA P02545 1/20 0.53
HPGD P15428 1/20 0.53
HTT P42858 1/20 0.53
RAB9A P51151 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6866879 0.91 PDGFRB (0.63) FLT3PDGFRBPDGFRAMEN1CYP1A2
SCHEMBL6865628 0.89 PDGFRB (0.60) FLT3PDGFRBPDGFRAMEN1CYP1A2
SCHEMBL6866896 0.85 FLT3 (0.67) FLT3PDGFRBPDGFRAMEN1CYP1A2
SCHEMBL6865348 0.84 GRIK1 (0.56) KDM4EALDH1A1HPGDL3MBTL1
SCHEMBL7685387 0.80 PDGFRB (0.60) FLT3PDGFRBPDGFRAMEN1CYP1A2
SCHEMBL6871064 0.79 KDM4E (0.57) MEN1KMT2AKDM4ENPC1ALDH1A1
SCHEMBL6865103 0.78 FLT3 (1.00) FLT3PDGFRBPDGFRAMEN1CYP1A2
SCHEMBL6866887 0.77 PDGFRB (1.00) FLT3PDGFRBPDGFRAMEN1CYP1A2
SCHEMBL6864433 0.76 PDGFRB (0.67) FLT3PDGFRBPDGFRAMEN1CYP1A2
SCHEMBL29354248 0.75 MEN1 (1.00) FLT3PDGFRBPDGFRAMEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6812243-B2 AS TYROSINE KINASE INHIBITORS; FOR THERARPY OF TUMORS, ARTERIOSCLEROSIS, RESTENOSIS AFTER BALLOON ANGIOPLASTY, ARTHRITIS AND FIBROTIC DISEASES ZENTARIS AG (DE) 2004-11-02 US disclosed
US-20030008898-A1 Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation ZENTARIS AG (DE) 2003-01-09 US disclosed
US-6407102-B1 TYROSINE KINASE AND PLATELET-DERIVED GROWTH FACTOR INHIBITORS; ANTICARCINOGENIC, ANTITUMOR, ANTIARTHRITIC AND ANTIPROLIFERATIVE AGENTS; RESTENOSIS, ARTERIOSCLEROSIS ZENTARIS AG (DE) 2002-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030008898-A1 Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation MKI67, IDO1, CCNI FLT3 230/4885PDGFRB 474/4885PDGFRA 542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.